reports
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty P...
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement MacroGenics received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard)MacroGenics’ cash runway extended through first half of 2027 ROCKVILLE, MD, June 10, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that it has entered into a royalty purchase agreement with Sagard i...
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthc...
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company’s management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL. A webcast of the above presentation may be accessed under ...
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equit...
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference. The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience. Details: ...
- Jonathan Moreland
TRS TRIMAS CORPORATION
PLUG PLUG POWER INC.
PENN PENN NATIONAL GAMING INC.
PEB PEBBLEBROOK HOTEL TRUST
MMLP MARTIN MIDSTREAM PARTNERS L.P.
JRVR JAMES RIVER GROUP HOLDINGS LTD
GLP GLOBAL PARTNERS LP
PATK PATRICK INDUSTRIES INC.
NEWT NEWTEK BUSINESS SERVICES INC.
RLMD RELMADA THERAPEUTICS
ELY CALLAWAY GOLF COMPANY
FLWS 1-800-FLOWERS.COM CL A
GBLI GLOBAL INDEMNITY PLC
SNDX SYNDAX PHARMACEUTICALS
HAIN THE HAIN CELESTIAL GROUP
NHF INC.
BRT NEXPOINT CREDIT STRATEGIES FUN
OCSL BRT APARTMENTS
MPB OAKTREE SPECIALTY LENDING CORPORATION
FGBI MID PENN BANCORP INC.
MIDD FIRST GUARANTY BANCSHARES
ENR THE MIDDLEBY CORPORATION
AVTR EDGEWELL PERSONAL CARE COMPANY
ZYME AVANTOR
VLA INC.
ONEW ZYMEWORKS INC.
ADV ARBOR METALS
DLHC ONEWATER MARINE
CVRX ADVANTAGE SOLUTIONS INC (A)
PFBX DALEIGH HOLDINGS CORP
TCRX CVRX
STGW INC.
OPAL PEOPLES FINANCIAL CORP. (MISSISSIPPI)
PRME FIRST EAGLE ALTERNATIVE CAPITAL BDC INC
STRW STAGWELL INC
PHIN OPAL FUELS INC
SRBK PRIME MEDICINE INC
SDHC STRAWBERRY FIELDS REIT INC.
FIP PHINIA INC
SUNS SR BANCORP INC
EVM SMITH DOUGLAS HOMES CORP
TXO FTAI INFRASTRUCTURE INC
GF SUNRISE REALTY TRUST
FG EATON VANCE INSD CALIF MUN BD FD
GREE MORNINGSTAR PARTNERS
HCWB L.P.
IAE THE NEW GERMANY FUND
FINS INC.
F AND G ANNUITIES AND LIFE
INC.
GREENIDGE GENERATION HLDGS INC
HCW BIOLOGICS INC
ING ASIA PACIFIC HIGH DIVIDEND EQUITY INCOME FUND
ANGEL OAK FINANCIAL STRATEGIES INCOME TERM TRUST
Kalaris to Participate at Stifel Ophthalmology Forum
Kalaris to Participate at Stifel Ophthalmology Forum PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate at an upcoming Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum. Details: Type: Fireside ChatSpeakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical OfficerDate: Tuesday, May 27th, 2025Time: 08:00 am ETLoca...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
PLUG PLUG POWER INC.
MAIN MAIN STREET CAPITAL CORPORATION
PATK PATRICK INDUSTRIES INC.
ELY CALLAWAY GOLF COMPANY
UEIC UNIVERSAL ELECTRONICS INC.
UIHC UNITED INSURANCE HOLDINGS CORP.
FLWS 1-800-FLOWERS.COM CL A
SNDX SYNDAX PHARMACEUTICALS
NNBR NN
OCSL INC.
MPB OAKTREE SPECIALTY LENDING CORPORATION
ENR MID PENN BANCORP INC.
ZYME EDGEWELL PERSONAL CARE COMPANY
ARQT ZYMEWORKS INC.
HQL ARCUTIS BIOTHERAPEUTICS
ADV INC.
CVRX TEKLA LIFE SCIENCES INVESTORS
SRPT ADVANTAGE SOLUTIONS INC (A)
DMA CVRX
SUNS INC.
EVM SAREPTA THERAPEUTICS
TXO INC.
GF DESTRA MULTI ALTERNATIVE FUND
FG SUNRISE REALTY TRUST
IAE EATON VANCE INSD CALIF MUN BD FD
MORNINGSTAR PARTNERS
L.P.
THE NEW GERMANY FUND
INC.
F AND G ANNUITIES AND LIFE
INC.
ING ASIA PACIFIC HIGH DIVIDEND EQUITY INCOME FUND
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rul...
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 461,000 shares of Tenaya common stock to three new non-executive employees in connection with the commencement of their employment. The stock options have an exerci...
Xos Delivers First Quarter Results, Highlighting GAAP Margin Gains
Xos Delivers First Quarter Results, Highlighting GAAP Margin Gains Achieved positive gross margin of approximately 20%, for the first quarter 2025 LOS ANGELES, May 14, 2025 (GLOBE NEWSWIRE) -- Xos, Inc. (NASDAQ: XOS) (“Xos” or the “Company”), a leading electric truck manufacturer and fleet services provider, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights: Delivered 29 units and generated $5.9 million in revenue during the first quarter of 2025, compared to 62 units and $13.2 million in revenue in the first...
Kalaris Reports First Quarter 2025 Financial Results and Provides Busi...
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025 Cash and cash equivalents of $101M as of March 31, 2025, expected to fund operations into Q4 2026 PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinica...
MacroGenics Provides Update on Corporate Progress and First Quarter 20...
MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC, expected in second half of 2025 Advancement in portfolio of innovative ADC product candidates, including MGC026, MGC028 and MGC030 Cash, cash equivalents and marketable securities of $154.1 million as of March 31, 2025 ROCKVILLE, Md., May 13, 2025 (GLOBE NEWSWIRE...
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and ...
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will present five abstracts at the upcoming American Society ...
CPS Announces First Quarter 2025 Earnings
CPS Announces First Quarter 2025 Earnings Revenues of $106.9 million compared to $91.7 million in the prior year periodNet income of $4.7 million, or $0.19 per diluted shareTotal portfolio balance of $3.615 billion, highest in company historyNew contract purchases of $451.2 million LAS VEGAS, NV, May 12, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced earnings of $4.7 million, or $0.19 per diluted share, for its first quarter ended March 31, 2025. This compares to a net income of $4.6 million, or $0.19 per diluted share, ...
CPS Announces $419.95 Million Senior Subordinate Asset-Backed Securiti...
CPS Announces $419.95 Million Senior Subordinate Asset-Backed Securitization LAS VEGAS, Nevada, May 12, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) announced the closing of its second term securitization in 2025 on Monday May 12, 2025. The transaction is CPS's 55th senior subordinate securitization since the beginning of 2011 and the 38th consecutive securitization to receive a triple “A” rating from at least two rating agencies on the senior class of notes. In the transaction, qualified institutional buyers purchased $419....
CPS to Host Conference Call on First Quarter 2025 Earnings
CPS to Host Conference Call on First Quarter 2025 Earnings Las Vegas, Nevada, May 09, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced that it will hold a conference call on Tuesday, May 13, 2025 at 1:00 p.m. ET to discuss its first quarter 2025 operating results. Those wishing to participate can pre-register for the conference call at the following link . Registered participants will receive an email containing conference call details for dial-in options. To avoid delays, we encourage participants to dial into the confere...
Xos, Inc. Announces First Quarter 2025 Earnings Release Date and Confe...
Xos, Inc. Announces First Quarter 2025 Earnings Release Date and Conference Call LOS ANGELES, May 09, 2025 (GLOBE NEWSWIRE) -- Xos, Inc. (NASDAQ: XOS), a leading electric truck manufacturer and fleet services provider, announced it is scheduling the release of its first quarter 2025 operating results on Wednesday, May 14, 2025 after the close of the U.S. financial markets. Management will host a conference call to discuss these financial results at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that same day. Conference Call and Webcast Details Date / Time:Wednesday, May 14, 2025, at 4...
Consumer Portfolio Services Deploys AI-Powered Servicing Platform from...
Consumer Portfolio Services Deploys AI-Powered Servicing Platform from Salient to Advance Collections Strategy LAS VEGAS, NV, May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CPSS) (“CPS” or the “Company”), a leader in providing indirect automobile financing to consumers, today announced the deployment of a next-generation AI-powered servicing and collections platform developed in partnership with Salient, a leading provider of AI voice agent solutions tailored for the automotive industry. As Consumer Portfolio Services continues to scale its loan portfolio and optimize servicing operations, S...
Tenaya Therapeutics Reports First Quarter 2025 Financial Results and P...
Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Interim Data from Low Dose Cohort in MyPEAKTM-1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification RIDGE Natural History and Seroprevalence Study Highlights Significant Disease Burden and Unmet Need Among Adults with PKP2-associated ARVC Data Readouts for TN-201 and TN-401 Clinical Programs On Track for the Second Half of 2025 Cash Runway Extended into Second Half of 2026 SOUTH SAN FRANCISCO, Calif., ...
MacroGenics Announces Date of First Quarter 2025 Financial Results
MacroGenics Announces Date of First Quarter 2025 Financial Results ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025. The Company will not be hosting a conference call to discuss its financial results or corporate progress for the quarter ended Marc...
MacroGenics to Participate in Upcoming Investor Conference
MacroGenics to Participate in Upcoming Investor Conference ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will participate in the following investor conference this month: The Citizens Life Sciences Conference (New York). Members of MacroGenics’ management team will participate in a fireside chat on Thursday, May 8, 2025, at 10:3...
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History ...
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025 RIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in the PKP2 Gene Patients Experience High Burden of Arrhythmias and Severe Disease Progression Despite Standard-of-Care Treatments Large Majority of PKP2-associated ARVC Patients Appear Eligible for TN-401 Gene Therapy Based on Low Rates of Preexisting Immunity to AAV9 Antib...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.